29 Jan 2025 22:15 CET

Issuer

NANOBIOTIX

PARIS and CAMBRIDGE, Mass., Jan. 29, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX(link is external) (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conferences:

Guggenheim SMID Cap Biotech Conference
Date: Thursday, February 6, 2025
Time: 1pm ET / 7pm CET
Location: New York, NY
Presenter: Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix
Webcast link: Click here(link is external)

Leerink Global Healthcare Conference
Date: Wednesday, March 12, 2025
Time: 10:40pm ET / 4:40pm CET
Location: Miami, FL
Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix
Webcast link: Click here(link is external)

The fireside chats will be webcast live from the events page(link is external) of the Investors section of the Company’s website. Replay of the webcast will be available following the event.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com(link is external) or follow us on LinkedIn(link is external) and Twitter(link is external).

Contacts

Nanobiotix 
Communications Department
Brandon Owens
VP, Communications
+1 (617) 852-4835
contact@nanobiotix.com
Investor Relations Department
Craig West
SVP, Investor Relations
+1 (617) 583-0211
investors@nanobiotix.com
 
  
Media Relations 


France – HARDY
Caroline Hardy
+33 06 70 33 49 50
carolinehardy@outlook.fr(link sends email)

  
Global – LifeSci Advisors
Kevin Gardner
+1 (617) 283-2856
kgardner@lifesciadvisors.com(link sends email)
 

 

Attachments


Source

Nanobiotix S.A.

Provider

GlobeNewswire

Company Name

NANOBIOTIX

ISIN

FR0011341205

Symbol

NANO

Market

Euronext